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A B S T R A C T
Background and objective: The VALGENT framework is developed to assess the clinical performance of HPV tests
that offer genotyping capability. Samples from the VALGENT-3 panel are used to identify an optimal viral
concentration threshold for the RIATOL qPCR HPV genotyping assay (RIATOL qPCR) to assure non-inferior
accuracy to detect high-grade cervical intraepithelial neoplasia (CIN), compared to Qiagen Hybrid Capture 2
(HC2), a standard comparator test validated for cervical cancer screening.
Study design: The VALGENT-3 panel comprised 1300 samples from women participating in the Slovenian cer-
vical cancer screening programme, enriched with 300 samples from women with abnormal cytology. In follow-
up, 126 women were diagnosed with CIN2+ (defined as diseased) and 1167 women had two consecutive ne-
gative Pap smears (defined as non-diseased). All 1600 samples were analyzed with the RIATOL qPCR. Viral
concentration was expressed as viral log10 of the number of copies/ml. A zone of viral concentration cut-offs was
defined by relative ROC analysis where the sensitivity and specificity were not inferior to HC2.
Results: The RIATOL qPCR had a sensitivity and specificity for CIN2+ of 97.6% (CI: 93.2–99.5%) and 85.1% (CI:
82.9–87.1%), respectively, when the analytical cut off was used. At a cut off of 6.5, RIATOL qPCR had a sen-
sitivity of 96.0% (CI: 91.0–98.7%) and a specificity of 89.5% (87.6–91.2%). At optimized cut off, accuracy of the
qPCR was non-inferior to the HC2 with a relative sensitivity of 1.00 [CI: 0.95–1.05 (p=0.006)] and relative
specificity of 1.00 [CI: 0.98–1.01 (p=0.0069)].
Conclusions: The RIATOL qPCR has a high sensitivity and specificity for the detection of CIN2+ . By using a
fixed cut-off based on viral concentration, the test is non-inferior to HC2. HPV tests that provide viral con-
centration measurements or other quantifiable signals allow flexibility to optimize accuracy required for cervical
cancer screening.
1. Background and objectives
Human papillomaviruses (HPV), common sexually transmitted
viruses with more than 200 genotypes, are the principal cause of
cervical cancer. Twelve high-risk HPV (hrHPV) genotypes (HPV16,
HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52,
HPV56, HPV58 and HPV59) are recognised by the International Agency
for Research on Cancer (IARC) as class I or IIa carcinogens [1].
https://doi.org/10.1016/j.jcv.2019.09.008
Received 6 May 2019; Received in revised form 5 September 2019; Accepted 17 September 2019
Abbreviations: AGC, atypical glandular cells; ASC-H, atypical squamous cells, cannot exclude high-grade lesion (ASC-H); ASC-US, atypical squamous cells of
undetermined significance; CIN, cervical intraepithelial neoplasia; EIA, GP5+/6+ PCR-based enzyme immunoassay; HC2, qiagen hybrid capture 2; HSIL, high-grade
squamous intraepithelial lesion; hrHPV, high-risk human papillomavirus; LSIL, low-grade squamous intraepithelial lesions; NILM, negative for intraepithelial lesion
or malignancy; RIATOL, qPCR RIATOL qPCR HPV genotyping assay; VALGENT, VALidation of HPV GENotyping tests
⁎ Corresponding author at: Belgian Cancer Centre/Unit of Cancer Epidemiology, Sciensano, Julliete Wytsmanstraat 14, 1050 Brussels, Belgium.
E-mail address: Marc.arbyn@Sciensano.be (M. Arbyn).
1 shared first author.
2 shared last author.
Journal of Clinical Virology 120 (2019) 57–62
1386-6532/ © 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
Current cervical cancer screening recommendations are being re-
vised towards primary HPV testing [2,3]. Many HPV assays, that are
currently used in clinical practice identify hrHPV genotypes as a group
with limited genotyping capacity (often with separate identification of
HPV16 and HPV18 only). HPV full genotyping assays (separate iden-
tification of all hrHPV genotypes) can be important in risk-based
management of screen-positive women, as marker for the detection of
minimal residual disease after treatment for cervical lesions and to
monitor vaccination effects.
Several HPV assays generate a signal which increases in strength
with the amount of virus present in the sample and use this signal to
generate a dichotomous result. However, the quantitative value of the
signal can be used to adapt the optimal clinical threshold to assure
satisfactory accuracy for detection of high-grade cervical intraepithelial
neoplasia (CIN) lesions in a screening population. Exact quantitative
values are rarely used for reporting HPV results since their clinical/
prognostic value is still a matter of ongoing debate [4–9].
Given the multitude of commercially available HPV tests, validated
assays which assure high-quality screening needs to be identified. A
collaborative framework VALidation of HPV GENotyping Tests
(VALGENT) [10] allows verification of minimal criteria that needs to be
fulfilled for the use of any HPV assays in primary cervical cancer
screening. In clinical practice, only clinically validated assays should be
used and continuous monitoring of test performance is necessary to
assure optimal safety of HPV-based screening programs [1,11,12].
The RIATOL qPCR HPV genotyping assay is a laboratory developed
test (RIATOL qPCR, Antwerp, Belgium) [13] which has been routinely
used in Algemeen Medisch Laboratorium (AML, Sonic healthcare, An-
twerp, Belgium) for more than 12 years. It has been accredited
(ISO15189) and validated according to the international criteria for
HPV DNA tests to be used in primary cervical cancer screening settings
[11,14]. Besides a qualitative result for 14 hrHPV genotypes (class I and
IIA carcinogenic HPV genotypes plus HPV66 and HPV68), the assay
also quantifies viral concentration (VC) of each targeted HPV genotype.
In this study, we assessed the clinical performance of RIATOL qPCR
through the third instalment of VALGENT project (VALGENT-3) and to
identify the optimal clinical VC cut-offs to assure that the test fulfils the
required accuracy performance criteria for primary cervical cancer
screening.
2. Study design
2.1. Sample collection
The collection of specimens used for the present iteration of
VALGENT-3 was performed in Slovenia, as previously reported
[15–19]. In brief, from December 2009 to August 2010, 1300 con-
secutive cervical samples were collected from women aged 25–64 years
who participated in the Slovenian national cervical cancer screening
programme (screening population). Additionally, from January 2014 to
May 2015, this collection was enriched with 300 cytological abnormal
specimens (enrichment population), which included 100 women with
atypical squamous cervical cells of undetermined significance (ASC-
US), 100 women with low-grade squamous intraepithelial lesion (LSIL)
and 100 women with high-grade squamous intraepithelial lesion
(HSIL). Ethical approval was obtained from the Medical Ethics Com-
mittee of the Republic of Slovenia (consent numbers: 83/11/09 and
109/08/12).
All samples were stored in ThinPrep PreservCyt solution (Hologic,
Marlborough, MA, USA) at −70 °C with aliquots disseminated in the
Laboratory for Molecular Microbiology of the Faculty of Medicine,
University of Ljubljana, Slovenia to participating laboratories for
testing with different HPV assays.
In January 2016, samples of 1ml of the original ThinPrep aliquot
was sent on dry ice to AML, Department of Molecular Diagnostics,
Antwerp, Belgium. Samples were handled with care to avoid
contamination during storage, aliquoting, transfer to and reception at
AML. Upon arrival at AML, samples were stored at−80 °C until further
processing.
2.2. Cytology
Conventional cytology was performed in accordance with the
standard routine gynaecological practice in Slovenia and in agreement
with the European guidelines [20]. Results were classified according to
the 2001 Bethesda system [21].
2.3. Hybrid capture 2 testing
Hybrid Capture 2 (HC2) testing was done according to the manu-
facturer’s instructions. HC2 detects 13 hrHPV genotypes in aggregate
((class I and IIA carcinogenic HPV genotypes plus HPV68) and was used
as the standard comparator test for the assessment of the clinical per-
formance of the RIATOL qPCR.
2.4. RIATOL qPCR
The RIATOL qPCR is a fully automated, clinically validated la-
boratory developed HPV test [13,22]. Processing of the samples was
performed in batches of 91 samples. After thawing, samples were vor-
texed rigorously and transferred manually to a 96 deep-well block. DNA
was extracted from the cervical samples using the Cervista MTA system
(Hologic, Bedford, MA, USA), in combination with the Genfind DNA
extraction kit. Subsequently, the DNA was amplified using a series of
real-time qPCR reactions on the LightCycler 480 type I (Roche Mole-
cular Systems, Pleasanton, California, USA). The presence of 14 dif-
ferent hrHPV genotypes is determined using TaqMan based real-time
PCR reactions targeting type specific) [13] sequences of viral genes
(HPV16 E7, HPV18 E7, HPV31 E6, HPV33 E6, HPV35 E6, HPV39 E7,
HPV45 E7, HPV51 E6, HPV52 E7, HPV56 E7, HPV58 E6, HPV59 E7,
HPV66 E6, HPV68 E7). The PCR reactions are done in ultra-low volume
(6 μl) and are performed in 8 multiplex reactions. Cellularity control is
performed on every sample by amplification of the beta-globin gene.
Quantification of the amount of HPV in a sample was determined
from type specific standard curves constructed from serial dilutions of
known quantities of type specific synthetic gene constructs (g-block,
Integrated DNA Technologies(IDT), Coralville, Iowa, USA). These re-
sults, expressed as the number of copies per μl extracted DNA were used
to calculate the VC of type specific HPV copies per ml ThinPrep sus-
pension using the following equation:
VC=Cdna x Velu / Vinp
Where:
VC= viral concentration (copies HPV per ml sample)
Cdna = copies HPV per μl DNA (copies/μl)
Velu = elution volume DNA extraction (μl)
Vinp = input volume sample for DNA extraction (ml)
The lower level of detection (LOD) for the Riatol qPCR assay is 4
log10 copies/ml. Results were reported as hrHPV negative, hrHPV po-
sitive or inconclusive. Based on the beta-globin standard curve, DNA
concentration (ng/μl) was determined in every sample. Samples with a
DNA concentration below 0.12 ng/μl were considered as invalid and
reported as inconclusive. This cut-off was chosen based on extensive
analyses demonstrating that, below this cut-off, consistency is not
guaranteed. An inconclusive result included no or insufficient material/
cells for analysis. A sample was considered analytically HPV negative if
none of the 14 hrHPV tests showed a positive signal and the beta-globin
DNA concentration was above 0.12 ng/μl. HrHPV positivity was defined
using two types of cut-off: 1) an analytical cut-off, which corresponded
with the lowest threshold yielding a measurable signal, and 2) an op-
timised clinical cut-off, yielding the best compromise in clinical
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accuracy, as explained below. For all positive samples, VCs were ex-
pressed as the log10(copies/ml). In samples with multiple hrHPV in-
fections, only the concentration of the hrHPV genotype with the highest
concentration was used for further analysis.
2.5. Clinical outcome and performance measurements
Follow-up and management of the patients with abnormal cytology
result was done according to the Slovenian national guidelines [23],
and the detailed algorithm has been described in previously published
reports [15–19,24].
The histologically confirmed cervical intraepithelial neoplasia grade
2 or worse (CIN2+) were considered as the clinical disease outcome
and used for the computation of clinical sensitivity. We considered
Women with two consecutive cytological results of negative for in-
traepithelial lesion or malignancy (NILM) (at enrolment and subsequent
screening 12–48 months later) were grouped as non-diseased and used
for the computation of clinical specificity for≤ CIN1.
2.6. Statistical analysis
The clinical sensitivity and specificity of RIATOL qPCR for CIN2+
and CIN3+ were computed and compared to HC2 using the non-in-
feriority score test [14,25], accepting 0.90 and 0.98 as benchmarks for
relative sensitivity and relative specificity, respectively [26]. Statisti-
cally significant non-inferiority was accepted when the one-sided p
value was<0.05 [25]. All analyses were performed using STATA
version 14 (College Station, TX, USA).
ROC curve analysis was performed to assess the trade-off between
sensitivity and specificity as a function of the VC. Subsequently, the
range of VC was identified where the clinical sensitivity and specificity
was not inferior to that of the HC2. Statistically this translated to find
the minimal and maximal VC, where the lower 90% confidence interval
(CI) around the relative sensitivity exceeded 0.90 and the lower 90% CI
around the relative specificity exceeded 0.98. Ninety percent CIs were
used since this correspond approximately with 0.05 confidence level for
one-sided non-inferiority testing [11].
3. Results
3.1. RIATOL qPCR HPV analytical genotyping prevalence
The characteristics of the VALGENT-3 population in terms of de-
mographics, cytological and histological results has been reported
previously [15–19,24]. Of the 1600 VALGENT-3 samples analysed with
the RIATOL qPCR, 56 (3.5%) had a human DNA concentration below
the cut-off of 0.12 ng/μl. These samples were considered as invalid and
excluded from further analysis, although these group comprises one
CIN2+ case. Of the 1544 remaining samples, 217 (17.4%) women in
the screening population (N=1249) and 80 (27.1%) women in the
enrichment population (N=295) tested positive for the presence of
hrHPV. The overall and type-specific prevalence of 14 hrHPV genotypes
stratified according to the baseline cytology is shown in Table 1. HPV
was more prevalent in women with abnormal cytology compared to
women with normal cytological results. When samples were tested with
RIATOL qPCR considering the 13 hrHPV genotypes targeted by HC2,
the prevalence of hrHPV in NILM, ASC-US, LSIL and HSIL were 13.9%,
45.3%, 72.7% and 84.5%, respectively.
3.2. Accuracy of the RIATOL qPCR using the analytical cut-off
The RIATOL qPCR and HC2 results stratified for the outcomes
CIN2+, CIN3+ and≤ CIN1 using the analytical cut-off are presented
in Table 2. The clinical sensitivity of the RIATOL qPCR using the ana-
lytical cut-off was 97.6% (95%CI, 93.2–99.5%) and 100.0% (95%CI,
95.5–100%) for CIN2+ and CIN3+, respectively. When the analysis is
Table 1
Overall and type-specific prevalence of hrHPV genotypes in the total study
population by baseline cytology result, using HC2 and RIATOL qPCR (with
analytical cut-off).
Assay and HPV
genotypes
No (%) with virological result, by cytology category:
NILM
(N=1189)a
ASC-US
(N=128)
LSIL
(N=110)
HSIL+
(N=113)
HC2
hrHPVb 125 (10.5) 63 (49.2) 85 (77.3) 97 (85.8%)
RIATOL qPCR
hrHPV (13
genotypes)c
165 (13.9) 58 (45.3) 80 (72.7) 95 (84.1)
hrHPV (14
genotypes)d
182 (15.33) 64 (50.0) 85 (77.3) 99 (87.6)
HPV 16 25 (2.1) 11 (8.6) 28 (25.5) 56 (49.6)
HPV 18 12 (1.0) 8 (6.3) 9 (8.2) 11 (9.7)
HPV 31 37 (3.1) 18 (14.1) 23 (20.9) 19 (16.8)
HPV 33 11 (0.9) 6 (4.7) 7 (6.4) 7 (6.2)
HPV 35 3 (0.3) 1 (0.8) 1 (0.9) 1 (0.9)
HPV 39 18 (1.5) 3 (2.3) 5 (4.6) 3 (2.7)
HPV 45 5 (0.4) 5 (3.9) 4 (3.6) 6 (5.3)
HPV 51 24 (2.0) 4 (3.1) 9 (8.2) 6 (5.3)
HPV 52 18 (1.5) 9 (7.0) 8 (7.3) 7 (6.2)
HPV 56 11 (0.9) 6 (4.7) 11 (10.0) 6 (5.3)
HPV 58 11 (0.9) 3 (2.3) 11 (10.0) 8 (7.1)
HPV 59 21 (1.8) 3 (2.3) 4 (3.6) 2 (1.8)
HPV 66 21 (1.8) 11 (8.6) 9 (8.2) 6 (5.3)
HPV 68 26 (2.2) 7 (5.5) 9 (8.2) 4 (3.5)
hrHPV
(14genotypes)e
128 (10.8) 55 (43.0) 81 (73.6) 96 (85.0)
a Cytological negative samples (NILM) are only from the screening popula-
tion.
b Positive for at least one of 13 hrHPV genotypes (HPV16, HPV18, HPV31,
HPV33, HPv35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59,
HPV68).
c Positive for at least one of the 13 hrHPV genotypes targeted by HC2 with
the RIATOL qPCR.
d Positive for at least one of 14 hrHPV genotypes with the RIATOL qPCR (13
genotypes targeted by HC2+HPV66).
e considering the optimised clinical cut-off; NILM, negative for in-
traepithelial lesion or malignancy; ASC-US, atypical squamous cells of un-
determined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL,
high-grade squamous intraepithelial lesion.
Table 2
Relative sensitivity for CIN2+ and CIN3+ and relative specificity for≤ CIN1
of the RIATOL qPCR assay versus HC2 in the total study population (using the
analytical cut-off).
Clinical outcome HPV test HC2+ HC2- Total
CIN2+ (N=126) RIATOL qPCR+ 120 3 123
RIATOL qPCR- 1 2 3
Total 121 5 126
Relative sensitivity RT/HC2 for CIN2+: 1.02 (0.97–1.06),
pn.inf = 0.0001
CIN3+ (N=81) RIATOL qPCR + 79 2 81
RIATOL qPCR - 0 0 0
Total 79 2 81
Relative sensitivity RT/HC2 for CIN3+: 1.03
(0.99–1.06), pn.inf < 0.0001
≤CIN1 (N=1167) RIATOL qPCR+ 100 74 174
RIATOL qPCR- 20 973 993
Total 120 1047 1167
Relative specificity RT/HC2 for≤ CIN1: 0.95 (0.92–0.98),
pn.inf = 0.9998
*pn.inf. < 0.05 means that the sensitivity or specificity of the RIATOL qPCR
assay are not significantly lower than that of the HC2, accepting the bench-
marks of 0.90 and 0.98 for relative sensitivity and relative specificity, respec-
tively.
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restricted to women>30 years, absolute sensitivities were similar
(Supplementary Table 1). The specificity of the RIATOL qPCR
for≤ CIN1 was 85.1% (95%CI, 82.9–87.1%) in the total study popu-
lation and slightly higher when analysis was restricted to women>30
years, 87.5% (95%CI, 85.3–89.5%).
The relative clinical performance of the RIATOL qPCR compared to
HC2 is presented in Table 2. When using the analytical cut-off, the
RIATOL qPCR had a relative clinical sensitivity of 1.02 (95%CI,
0.97–1.06, Pn.inf = 0.0001) for CIN2+ and 1.03 (95%CI, 0.99–1.06,
Pn.inf < 0.0001) for CIN3+ . The relative clinical specificity of the
RIATOL qPCR assay for≤ CIN1 was 0.95 (95%CI, 0.92 to 0.98,
Pn.inf = 0.9998).
3.3. Clinical performance of the RIATOL qPCR with the optimized cut-off
Since non-inferiority was not reached for clinical specificity when
using the analytical cut-off, an algorithm was developed to calculate a
clinically relevant cut-off, which would result in non-inferior clinical
accuracy when compared to HC2. A ROC curve of the sensitivity as a
function of the false-positivity rate of the RIATOL qPCR to detect
CIN2+ was constructed (Fig. 1a). Subsequently, the variation in sen-
sitivity and specificity for CIN2+ was plotted as a function of the VC
(Fig. 1b). Next, the range of VC was identified where the clinical sen-
sitivity and specificity where not inferior to HC2 (Figs. 1b and 2 ).The
range where the requirements of non-inferior accuracy of the RIATOL
qPCR compared to HC2 are fulfilled was between 6.493 and 7.747. As
optimized clinical cut-off, the VC in this range with the highest sensi-
tivity is chosen for further analysis at 6.493.
Using the optimized cut-off, the absolute clinical sensitivity of
RIATOL qPCR for CIN2+ and CIN3+ in the total study population was
96.0% (95%CI, 91.0–98.7%) and 98.0% (95%CI, 91.4–99.7%), re-
spectively (Table 3), while the absolute clinical specificity for≤ CIN1
was 90.0% (95CI, 87.6–91.2%). Comparable results are found when the
analysis was limited to women aged 30 years or older (Supplementary
Table 2).
The relative clinical sensitivity and specificity of the RIATOL qPCR
compared to HC2 is presented in Table 3. When using the optimized
clinical cut-off, the RIATOL qPCR had a relative sensitivity of 1.00 for
CIN2+ (95%CI, 0.95–1.05) and 1.00 for CIN3+ (95%CI 0.95–1.05)
with a pn.inf of 0.0006 (CIN2+) and 0.0045 (CIN3+), and therefore
considered as non-inferior to HC2. The relative specificity of the
RIATOL qPCR assay for≤ CIN1 was 1.00 (95%CI, 0.98–1.01) and also
non-inferior to HC2 (pn.inf = 0.0069). Similar results were obtained
when the analysis was restricted to women>30 years (Supplementary
Table 2) (Table 4).
4. Discussion
In the present study, the clinical performance of the RIATOL qPCR
was compared to HC2 within the VALGENT-3 project. At the analytical
cut-off, non-inferiority criteria for screening, as defined by Meijer et al.
[26], was not reached for the clinical specificity. Therefore, a clinically
relevant viral concentration cut-off were analysed post-hoc, balancing
both sensitivity and specificity to meet the defined criteria. A zone of
Fig. 1. Part a. ROC curve of the sensitivity as a function of the false-positivity rate (1-specificity) of the RIATOL qPCR to detect CIN2+ . Part b: Variation in
sensitivity and specificity for CIN2+ as a function of the viral concentration expressed as log10 (HPV copies/ml of sample). In case of infection with multiple
genotypes, the HPV type with the highest concentration was chosen. Within the orange bar (range: 6.493.–7.747), international accuracy requirements for cervical
cancer screening tests are fulfilled.
Fig. 2. Plot of the left 90% confidence interval bound around the relative
sensitivity for CIN2+ against the relative specificity of the RIATOL qPCR vs
HC2 corresponding to viral concentration cut-off points. The orange zone of the
line (upper right corner) indicates the range where the requirement of non-
inferior accuracy compared to HC2 is fulfilled (viral concentration expressed as
log10[copies/ml]) ≥6.493 and< 7.747). Optimized cut-off = 6.493.
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VCs was identified by relative ROC curve analysis, where the accuracy
of the RIATOL qPCR was non-inferior to HC2. Within the defined range,
the minimum cut-off value was chosen as threshold. This calculated
threshold for screening purposes yields the highest sensitivity with the
specificity that still fulfils the proposed criteria.
In cases where multiple HPV infections were present, VC of the
hrHPV type with the highest concentration was used for further ana-
lyses. When the analysis was performed with the cumulative hrHPV
concentration, defined as the logarithm of the sum of the genotype-
specific concentrations of all present hrHPV genotypes, comparable
results were found (data not shown). Little is known about the influence
of an individual HPV genotype in the presence of multiple genotypes on
the carcinogenicity [27], therefore further research is necessary to
understand the complexity of multiple HPV infections. Since we re-
ported the VC for each HPV genotype separately, for the convenience of
the clinician a cut-off per genotype will facilitate the interpretation of
the results. For this reason, we choose to calculate the cut-off based on
the highest concentration. We are aware of this possible limitation.
Since HPV genotyping information of the biopsies was not available,
it was impossible to determine a genotype-specific cut-off. In addition,
the cohort used in this study was too small to get reliable and statisti-
cally significant results per each targeted hrHPV genotype. However,
the authors agree that this would be the ideal situation to have a clinical
cut off value per HPV genotype. More methodological research is
needed to find feasible clinical and or analytical validation concepts for
HPV genotyping tests at the type-specific level.
Riatol qPCR has been clinically validated based on a fixed Ct value
(Ct ≤34.00) [22]. This is the first study to calculate an optimized
clinical cut-off defined in terms of VC within the VALGENT-3 study.
Although there is an international WHO standard available for HPV 16
and 18, comparison of viral load measurements with other quantitative
assays is difficult. Consensus quantification strategies for calculation of
the amount of HPV particles present in a liquid based cytology sample
have not yet been reached and currently different calculation options
are used.
The presence of a large sample set and well documented follow-up
database, makes VALGENT study well suited for clinical validation of
multiple HPV genotyping test at the same time. To insure correct in-
terpretation of CT values, an additional QC standard must be included
in the assay.
VALGENT contributes in defining the list of HPV tests, which fulfil
the defined minimal requirements of HPV genotyping assays for use in
primary cervical cancer screening.
Our study demonstrates that HPV tests, providing viral concentra-
tions (or other quantifiable signals) allow flexibility to optimize the
clinical accuracy required for primary cervical cancer screening. This
technique is already applied in the paper of Viti et al. [18] where a
modification of the EUROArray HPV cut-off for HPV 16 makes the test
non inferior to HC2.
In the future, HPV assays that generate quantified outputs might
have an advantage compared to assays only producing a qualitative
output because of their adaptability for particular specimens (vaginal
self-samples, urine samples, other non-cervical specimens) or specified
clinical settings (vaccinated women, follow-up after treatment) or for
certain surveillance or research purposes (HPV vaccination trials, epi-
demiological studies, post vaccination surveillance of HPV infections).
Our team strongly supports the application of different cut-off values,
predefined according to specific situations/needs, i.e. primary
screening, follow-up, sample type, etc. Insights are based on historical
routine data, suggesting to be superior versus exploiting a fixed cut-off
(unpublished data). Future research is needed to confirm this.
In conclusion, by using the optimised cut-off based on viral con-
centration, the RIATOL qPCR test shows non-inferior sensitivity and
specificity for CIN2+ compared to the HC2 and fulfils the international
accuracy criteria for primary cervical cancer screening.
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Table 3
Relative clinical sensitivity for CIN2+ and CIN3+ and relative clinical speci-
ficity for≤ CIN1 of the RIATOL qPCR versus HC2 in the total population (using
the optimized clinical cut-off of 6.493 log10 copies/ml).
Clinical outcome HPV test HC2 + HC2 - Total
CIN2+ (N=126) RIATOL qPCR+ 118 3 121
RIATOL qPCR - 3 2 5
Total 121 5 126
Relative sensitivity RT/HC2 for CIN2+: 1.00 (0.95–1.05),
pn.inf = 0.0006
CIN3+
(N=81)
RIATOL qPCR+ 77 2 79
RIATOL qPCR - 2 0 2
Total 79 2 81
Relative sensitivity RT/HC2 for CIN3+: 1.00 (0.95–1.05),
pn.inf = 0.0045
≤CIN1
(N=1167)
RIATOL qPCR + 94 28 122
RIATOL qPCR- 26 1019 1045
Total 120 1047 1167
Relative specificity RT/HC2 for≤ CIN1: 1.00 (0.98–1.01),
pn.inf = 0.0069
*pn.inf. < 0.05 means that the sensitivity or specificity of the RIATOL q-PCR
assay are not significantly lower than that of the HC2, accepting the bench-
marks of 0.90 and 0.98 for relative sensitivity and relative specificity, respec-
tively.
Table 4
Absolute sensitivity and specificity of hrHPV testing of the RIATOL qPCR with different cut-offs to detect CIN2+ and the relative accuracy compared to HC2.
Cut-off
(log10 copies/ml)
Sensitivity RIATOL
qPCR, %
Relative sensitivity of RIATOL qPCR/
HC2 (90% CI)
pn.inf Specificity RIATOL
qPCR, %
Relative specificity of RIATOL qPCR/
HC2 (90% CI)
pn.inf
Analytical 97.6 1.02 (0.97–1.06) 0.0001 85.1 0.95 (0.92–0.98), 0.9998
6.493 96.0 1.00 (0.95–1.05) 0.0006 89.5 1.00 (0.98–1.01) 0.0069
7.747 91.3 0.95 (0.90–1.00) 0.0399 92.5 1.03 (1.01–1.06) <0.001
* pn.inf. < 0.05 means that the sensitivity or specificity of the RIATOL q-PCR assay are not significantly lower than that of the HC2, accepting the benchmarks of 0.90
and 0.98 for relative sensitivity and relative specificity, respectively.
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